During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

S Lional is supported by the Richard and Annelly Deets Fund for Multiple Myeloma and acts as a consultant for Millennium, Celgene, Novartis, Onyx, BMS, Merck and Acetylon. The authors have no ...

Celgene's European leader Tuomo Pätsi talks ... the most significant approval is for Revlimid as a first-line treatment for multiple myeloma. This expanded use is likely to confirm it as standard ...

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...

Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.

An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...